Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

Publisher： Karger

E-ISSN： 1423-0232|91|6|348-353

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.6, 2016-10, pp. : 348-353

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 136, Iss. 8, 2015-04 ,pp. : 1967-1975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Chemotherapy, Reexposure to Crizotinib and Treatment with a Novel ALK Inhibitor in a Patient with Acquired Crizotinib Resistance

By  

Respiration, Vol. 88, Iss. 3, 2014-08 ,pp. : 262-264

Karger

Access to resources Recommend Favorite

Rhamnetin Is a Potent Inhibitor of Extracellular Signal‐regulated Kinase 1 and c‐Jun N‐Terminal Kinase 1

By  

BULLETIN OF THE KOREAN CHEMICAL SOCIETY (ELECTRONIC), Vol. 36, Iss. 8, 2015-08 ,pp. : 2107-2110

John Wiley & Sons Inc

Access to resources Recommend Favorite

FN1: A novel fusion partner of ALK in an inflammatory myofibroblastic tumor

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 909-911

John Wiley & Sons Inc

Access to resources Recommend Favorite

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 10, 2015-11 ,pp. : 2513-2519

John Wiley & Sons Inc

Access to resources Recommend Favorite